{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gammaplex%2C+intravenous+immunoglobulin&page=9",
    "query": {
      "intervention": "Gammaplex, intravenous immunoglobulin",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 208,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gammaplex%2C+intravenous+immunoglobulin&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gammaplex%2C+intravenous+immunoglobulin&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T01:45:31.236Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01485796",
      "title": "Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency Diseases (PID)"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Infusion (Human), 10%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant human hyaluronidase",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2011-12-29",
      "completion_date": "2013-01-01",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-10-14T01:45:31.236Z",
      "location_count": 10,
      "location_summary": "Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Thornton",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Plymouth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01485796"
    },
    {
      "nct_id": "NCT03576469",
      "title": "A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "CVI - Common Variable Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "C1-esterase inhibitor [recombinant] (C1-INH-R)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "IMMUNOe Research Centers",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-06-13",
      "completion_date": "2020-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-02-15",
      "last_synced_at": "2026-10-14T01:45:31.236Z",
      "location_count": 1,
      "location_summary": "Centennial, Colorado",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03576469"
    },
    {
      "nct_id": "NCT04480424",
      "title": "Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "GAMUNEX-C",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Medical Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-09-17",
      "completion_date": "2021-10-25",
      "has_results": true,
      "last_update_posted_date": "2022-10-07",
      "last_synced_at": "2026-10-14T01:45:31.236Z",
      "location_count": 18,
      "location_summary": "Chandler, Arizona • Coronado, California • Chicago, Illinois + 15 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480424"
    },
    {
      "nct_id": "NCT06958796",
      "title": "Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cytomegalovirus",
        "Organ Transplant",
        "Kidney Transplant; Complications",
        "Liver Transplant Complications",
        "Simultaneous Liver-Kidney Transplantation; Complications"
      ],
      "interventions": [
        {
          "name": "Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Camille N. Kotton, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 80,
      "start_date": "2025-11-27",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-10-14T01:45:31.236Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Dallas, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06958796"
    },
    {
      "nct_id": "NCT03876288",
      "title": "Gastroparesis Outcome Longitudinal Database Enrolled Numerically",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gastroparesis"
      ],
      "interventions": [
        {
          "name": "GI Neuromodulation",
          "type": "DEVICE"
        },
        {
          "name": "Immunotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pyloric Therapies",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3000,
      "start_date": "2013-01-01",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-14T01:45:31.236Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03876288"
    },
    {
      "nct_id": "NCT00000117",
      "title": "Intravenous Immunoglobulin Therapy in Optic Neuritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Optic Neuritis"
      ],
      "interventions": [
        {
          "name": "Immunoglobulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "Up to 50 Years"
      },
      "enrollment_count": null,
      "start_date": "1995-08",
      "completion_date": "1997-12",
      "has_results": false,
      "last_update_posted_date": "2009-09-17",
      "last_synced_at": "2026-10-14T01:45:31.236Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000117"
    },
    {
      "nct_id": "NCT00001287",
      "title": "Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Demyelinating Diseases",
        "Paraproteinemias"
      ],
      "interventions": [
        {
          "name": "intravenous immunoglobulin (IVIg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 60,
      "start_date": "1990-12",
      "completion_date": "2001-01",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-14T01:45:31.236Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001287"
    },
    {
      "nct_id": "NCT02287467",
      "title": "Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza A",
        "Influenza B"
      ],
      "interventions": [
        {
          "name": "Intravenous hyperimmune immunoglobulin (IVIG)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for IVIG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 329,
      "start_date": "2015-01",
      "completion_date": "2018-06-07",
      "has_results": true,
      "last_update_posted_date": "2019-11-14",
      "last_synced_at": "2026-10-14T01:45:31.236Z",
      "location_count": 17,
      "location_summary": "San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02287467"
    },
    {
      "nct_id": "NCT02604810",
      "title": "Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "IGIV-C 10%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IGSC 20%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "2 Years to 75 Years"
      },
      "enrollment_count": 53,
      "start_date": "2016-01",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2019-10-04",
      "last_synced_at": "2026-10-14T01:45:31.236Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02604810"
    },
    {
      "nct_id": "NCT07674745",
      "title": "Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Therapeutic Plasma Exchange",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Intravenous immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Treatment as Usual",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 52,
      "start_date": "2026-10-01",
      "completion_date": "2031-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-14T01:45:31.236Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07674745"
    }
  ]
}